Short Communication: Preferential Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor

Area of Science:

• Virology
• Immunology
• Cell Biology

Background:

• HIV latency establishes a reservoir of infected cells, posing a significant challenge for viral eradication.
• Targeting latent HIV reservoirs is crucial for achieving a functional cure for HIV/AIDS.

Purpose of the Study:

• To investigate the efficacy of a MALT1 inhibitor, MI-2, in combination with bryostatin 1 for selectively eliminating latently HIV-infected cells.
• To elucidate the mechanisms underlying MI-2-mediated cell death in the context of HIV latency.

Main Methods:

• Utilized HIV-1 latently infected cell lines (ACH-2, Jurkat E4, J-LAT).
• Administered MALT1 inhibitor MI-2 and/or protein kinase C agonist bryostatin 1.
• Assessed cell death induction and correlated it with MCPIP1 expression and viral factors.

Main Results:

• The combination of MI-2 and bryostatin 1 significantly accelerated cell death in latently HIV-infected cells.
• MI-2-induced cell death was dependent on the presence of viral components.
• Cell death correlated with the induction of the cellular RNase MCPIP1.

Conclusions:

• The combination of MI-2 and bryostatin 1 demonstrates selective killing of latently HIV-infected CD4(+) T cells.
• This therapeutic strategy holds potential for targeting persistent HIV reservoirs.
• Further research is warranted to explore the clinical applicability of MALT1 inhibitors in HIV treatment.